Area of research
Infectious Diseases · Aerospace Engineering
Research interest
Research focused on Multiple myeloma and Placebo, with related work in Adverse effect, Lenalidomide, Tolerability. Notable publications include 'Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind,...', 'Clinical Outcome of Induction Treatment in the Era of Novel Agents and the Impact of the Number of High‐Risk Cytogenetic Abnormalities ( HRA ) on Prognosis of Patients With Newly...', and 'Clinical Outcome of Induction Treatment in the Era of Novel Agents and the Impact of the Number of High-Risk Cytogenetic Abnormalities (HRA) on Prognosis of Patients with Newly...'.
Clinical Outcome of Induction Treatment in the Era of Novel Agents and the Impact of the Number of High‐Risk Cytogenetic Abnormalities (<scp>HRA</scp>) on Prognosis of Patients With Newly Diagnosed Multiple Myeloma (<scp>NDMM</scp>): Insights From a Multicenter Study
Clinical Outcome of Induction Treatment in the Era of Novel Agents and the Impact of the Number of High-Risk Cytogenetic Abnormalities (HRA) on Prognosis of Patients with Newly Diagnosed Multiple Myeloma (NDMM): Insights from a Multi-Center Study
Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials